<DOC>
	<DOCNO>NCT00126165</DOCNO>
	<brief_summary>This study aim provide clinical evidence support refute current understanding biological sensitivity prostate cancer fractionate radiotherapy . Determining morbidity cancer control provide 4-week course treatment greatly influence future radiotherapy service patient localized prostate cancer .</brief_summary>
	<brief_title>Short-course Hypofractionated Radiotherapy Localized Prostate Cancer</brief_title>
	<detailed_description>This study aim provide clinical evidence support refute current understanding biological sensitivity prostate cancer fractionate radiotherapy . Determining morbidity cancer control provide 4-week course treatment greatly influence future radiotherapy service patient localized prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Stage T1 T2 prostate cancer Prostate specific antigen ( PSA ) &gt; =20 Gleason score &lt; =6 PSA &lt; =15 Gleason score 7 Signed inform consent No hip prosthesis , pin screws No previous pelvic radiotherapy No inflammatory bowel disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>hypofraction</keyword>
	<keyword>radiosensitivity</keyword>
	<keyword>image-guidance</keyword>
</DOC>